Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A)
- 244 Downloads
Recently, we reported that anticancer bioactive peptide (ACBP), purified from goat spleens immunized with human gastric cancer extracts, significantly inhibited gastric cancer cells in vitro and gastric tumors in vivo via repressing cell growth and promoting apoptosis, making it a promising potential biological anticancer drug. However, it is not known what genes are functionally required for the ACBP effects. Here, we first found that two tumor suppressor genes, cyclin-dependent kinase inhibitor 2B (CDKN2B) and growth arrest and DNA damage-inducible alpha (GADD45A), were upregulated significantly in the cells with ACBP treatment by microarray screening and the findings were validated by real-time RT-PCR. Next, GADD45A mRNA and protein expressions were downregulated in the gastric cancer cells by lentivirus-mediated RNAi; then, cell viability, cell cycle, and apoptosis were assayed by MTT and flow cytometry. Interestingly, our results indicated that cell viability was not dependent on GADD45A without ACBP treatment; however, cell sensitivity to ACBP was significantly decreased in ACBP-treated gastric cancer cells with GADD45A downregulation. Therefore, we demonstrate that GADD45A was functionally required for ACBP to inhibit gastric cancer cells, suggesting that GADD45A may become a biomarker for ACBP sensitivity. Our findings have significant implications on the molecular mechanism understanding, biomarker development, and anticancer drug development of ACBP.
KeywordsAnticancer bioactive peptide Gastric cancer Cell viability Apoptosis Cell cycle CDKN2B GADD45A
This research was supported by the National Natural Science Foundation (81160254).
- 3.Hou JF, Yan MR, Yan XH, Jiao TM, Rong YN, Su XL. Effect of anti-cancer bioactive peptide on leukemia mice. J Inn Mong Med Coll. 2004;26(1):3–6.Google Scholar
- 4.Yang ZY, Wang WL, Su XL. HPCE analysis of polypeptides isolated from goat spleens. Chin J Pharm Anal. 2005;10:1248–9.Google Scholar
- 5.Yang ZY, Zhang ZP, Su XL. MALDI-TOF-MS analysis of polypeptides isolated from goat spleens. Chin Pharm J. 2005;10:797.Google Scholar
- 6.Xu GH, Su XL, Shen JF, Bi, Xiaohui O. Control of anti-cancer bioactive peptide on the cell cycle of gastric cancer BGC-823. Chin J Clin Oncol. 2007;14:1361–4.Google Scholar
- 7.Zhao YY, Peng SD, Su XL. Effects of anti-cancer bioactive peptide on cell cycle in human nasopharyngeal carcinoma strain CNE. Chin J Otorhinolaryngol Head Neck Surg. 2006;41:607–11.Google Scholar
- 8.Jia SQ, Wang WL, Su XL. Inhibitory effect of anti-cancer bioactive peptide on proliferation of human breast cancer cell line nm231. Chin Med Biotechnol. 2007;2:270–5.Google Scholar
- 9.Su XL, Ying X, Cui HM, et al. And the mechanism of anti-cancer bioactive peptide on GBC-SD gallbladder cancer cells. Acta Anat Sin. 2007;38(Suppl):39–42.Google Scholar
- 10.Wang ZY, Yang CW, Oy XH, Su XL. Anti-cancer bioactive peptide-S induced apoptosis of hepatoma cells and cell cycle regulation. Chin J Lab Diagn. 2010;14:1–6.Google Scholar
- 11.Su X, Dong C, Zhang J, Su L, Wang X, Cui H, et al. Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer. Cell Biosci. 2014;4:7.PubMedCentralCrossRefPubMedGoogle Scholar